These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24173694)

  • 21. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
    Wang SY; Yang ZJ; Zhang L
    Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
    Hocking CM; Kichenadasse G
    Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging drugs for chemotherapy-induced emesis.
    Navari RM; Province PS
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
    Navari RM
    Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Nathan PC
    Paediatr Drugs; 2003; 5(9):597-613. PubMed ID: 12956617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
    Wang XF; Feng Y; Chen Y; Gao BL; Han BH
    Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
    Navari RM
    Drugs; 2013 Mar; 73(3):249-62. PubMed ID: 23404093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
    Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
    Gamble M; Carroll E; Wright GC; Glode AE
    J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    Yoodee J; Permsuwan U; Nimworapan M
    Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Mukhopadhyay S; Dutta P; Banerjee S; Bhattacharya B; Biswas S; M Navari R
    Future Oncol; 2021 Jun; 17(16):2041-2056. PubMed ID: 33792376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
    Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
    Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
    Rapoport BL; Herrstedt J; Snow RC; Radhakrishnan V; Saito M; Navari RM; Smit T
    Support Care Cancer; 2023 Dec; 32(1):36. PubMed ID: 38105286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
    Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.